New hope for Hard-to-Treat cancers: first human trial begins
NCT ID NCT06424665
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called FZ-AD005 in people with advanced solid tumors, especially small cell lung cancer and large cell neuroendocrine carcinoma. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 162 participants will be enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR, SCLC(SMALL CELL LUNG CANCER) OR LCNEC (LARGE CELL NEUROENDOCRINE CARCINOMA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hunan Cancer Hospital
RECRUITINGChangsha, Hunan, 410013, China
-
Shanghai East Hospital
RECRUITINGShanghai, Shanghai Municipality, 200120, China
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for rare tumors: tarlatamab trial opens
- New radioactive 'Smart Bomb' targets Hard-to-Treat lung cancer
- New combo attack on stubborn cancers shows promise in early trial
- New study maps cancer treatment journeys across latin america
- New hope for rare cancers: Triple-Drug attack shows promise
- New drug combo tested for tough cancers